Alemtuzumab (Campath) and Intron A
Determining the interaction of Alemtuzumab (Campath) and Intron A and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using alemtuzumab together with interferon alfa-2b may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The use of alemtuzumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Alemtuzumab alone may cause severe and prolonged myelosuppression, lymphopenia, and rarely, fatal bone marrow aplasia/hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia. Serious, sometimes fatal opportunistic infections have been reported, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.
- "Product Information. Campath (alemtuzumab)" Berlex, Richmond, CA.
Generic Name: alemtuzumab
Brand name: Campath, Lemtrada
Synonyms: Alemtuzumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alemtuzumab (Campath)-Intron-A (Interferon Alfa-2b Injection Solution)
- Alemtuzumab (Campath)-Intron-A (Interferon Alfa-2b Powder for Injection)
- Alemtuzumab (Campath)-Introvale
- Alemtuzumab (Campath)-Introvale extended-cycle
- Alemtuzumab (Campath)-Intuniv
- Alemtuzumab (Campath)-INU 600-EZS
- Intron A-Alemtuzumab (Lemtrada)
- Intron A-Alemtuzumab Intravenous
- Intron A-Alenaze-D
- Intron A-Alendronate
- Intron A-Alendronate and cholecalciferol
- Intron A-Alendronate Effervescent Tablets